Anti‐SARS‐CoV‐19 antibodies in children and adults with sickle cell disease: A single‐site analysis in New York City.

Anti-spike antibody levels significantly increased by exposure number (i.e., vaccination and/or infection, I R i SP 2 sp = 0.34, I p i < 0.001), but anti-nucleocapsid antibody levels did not (Figure 1E,F). Anti-spike and anti-nucleocapsid antibody levels were quantified in 36 patients with sickle cell disease (SCD) and 22 control patients without SCD seen in the same haematology adult and paediatric clinics. All SCD participants and 95% of controls had detectable anti-spike protein antibodies; 21 (58.3%) and 11 (50.0%) had anti-nucleocapsid antibodies, respectively. Keywords: antibodies; coronavirus 2019 (COVID-19); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); sickle cell disease; splenic function EN antibodies coronavirus 2019 (COVID-19) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sickle cell disease splenic function 680 683 4 08/10/22 20220815 NES 220815 Antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or vaccination reduces infection risk.1 In the United States, people with sickle cell disease (SCD) have experienced considerable complications from SARS-CoV-2 infection.2,3 Functional hyposplenia, asplenia, or splenectomy in SCD can increase pathogen susceptibility and reduce vaccine responsiveness.4 We evaluated serum antibody levels for anti-nucleocapsid antibodies from past infection and anti-spike antibodies from vaccination and/or past infection in people with SCD. [Extracted from the article]